Alexandre Yamada Fujimura Júnior

Alexandre Yamada Fujimura Júnior

Auto-generated profile, based on publicly available information

Alexandre Yamada Fujimura Júnior

Division of Medicine, Marilia medical school, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Current Eye Research
Verified
Journal Article
Closed access
MLMatheus Henrique Monteiro Leber
Matheus Henrique Monteiro Leber
TMTanize Louize Milbradt
Tanize Louize Milbradt
AFAlexandre Yamada Fujimura
Alexandre Yamada Fujimura
YSYasmin Picanco Silva
Yasmin Picanco Silva
Dillan Cunha AmaralDillan Cunha Amaral
Dillan Cunha Amaral
RBRubens Belfort
Rubens Belfort
Myopia is a significant public health concern with increased risk of ocular complications. Intense Foveal Red Light (IFRL) therapy has been explored in myopia control, but its efficacy at the pre-myopic stage remains underexplored. The use of this therapy in a population without a myopia diagnosis may offer a new window for the prophylactic application of IFRL therapy. The purpose of this meta-analysis is to determine the effectiveness of IFRL therapy in children with pre-myopia. PubMed, Embase, and the Cochrane Library were systematically searched for studies investigating the effects of IFRL therapy on myopia incidence, changes in axial length (AL), choroidal thickness (CT), and cycloplegic spherical equivalent refraction (SER). Two independent reviewers screened studies, extracted data, and assessed the risk of bias. Meta-analyses were conducted using random-effects models to estimate the pooled effect sizes. Of 365 studies identified, 4 met the criteria, totaling 619 participants (mean age 8.48 years, 51.8% female). At 6 months, IFRL significantly reduced myopia incidence (Risk Difference [RD] - 0.1; 95% CI -0.15 to -0.05; p < 0.01), with benefits persisting at 12 months (RD -0.17; 95% CI -0.26 to 0.09; p < 0.01). IFRL also reduced AL at 6 months (Mean Difference [MD] - 0.12 mm; 95% CI -0.16 to -0.09; p < 0.01) and 12 months (MD -0.18 mm; 95% CI -0.23 to -0.14; p < 0.01), increased CT (MD 22.34 µm; 95% CI 5.45-39.24; p < 0.01), and improved SER at 6 (MD 0.27 D; 95% CI 0.23 to 0.32; p < 0.01) and 12 months (MD 0.36 D; 95% CI 0.27-0.46; p < 0.01). IFRL effectively reduced myopia incidence, AL, and improved SER and CT. These findings support further research on its long-term efficacy and safety, particularly regarding potential adverse effects and durability of outcomes. Overall, IFRL may offer a preventive strategy for pre-myopic children.

18 February 2025 in Brazilian Journal of Anesthesiology (English Edition)
Verified
Journal Article
Open access
AJAlexandre Yamada Fujimura Júnior
Alexandre Yamada Fujimura Júnior
CMCarolina Braga Moura
Carolina Braga Moura
ASArnaldo Bastos dos Santos
Arnaldo Bastos dos Santos
Systematic review and meta-analysis to evaluate the efficacy of the Erector Spinae Plane Block (ESPB) in managing pain related to Herpes Zoster. We systematically searched PubMed, Embase, Cochrane Library, and CNKI for randomized trials comparing ESPB plus standard clinical treatment with clinical treatment alone. The population included patients with acute infection and those with Postherpetic Neuralgia (PHN). The primary outcome was pain intensity, and secondary outcomes included analgesic consumption. Mean Difference (MD) was used for continuous outcomes, and Risk Ratio (RR) for binary outcomes. Seven trials with 362 patients were included. ESPB significantly reduced pain up to eight weeks (MD = -1.21; 95% CI -2.17 to -0.24; I2 = 89%). In the subgroup analysis of patients in the acute stage, the benefit seemed to extend with pain reduction lasting up to 12-weeks (MD = -1.49; 95% CI -2.61 to -0.37; I2 = 0%), and a reduction in the incidence of PHN (RR = 0.49; 95% CI 0.28 to 0.85; I2: 0%). In the PHN subgroup, pain reduction was notable only at four weeks (MD = -1.08; 95% CI -1.81 to -0.35; I2 = 86%). ESPB also reduced acetaminophen (MD = -0.6 g.day-1; 95% CI -1.05 to -0.14; I2 = 49%) and pregabalin consumption (-68.58 mg.day-1; 95% CI -127.18 to -9.97; I2 = 41%) over 12 weeks. ESPB seems to provide pain relief in Herpes Zoster patients, with a prolonged benefit in the acute stage. Also, ESPB reduced the need for analgesics over 12 weeks. More research is needed to corroborate this practice. This article was prospectively registered in PROSPERO (www.crd.york.ac.uk/prospero, CRD42024566674).

2 June 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
RGRamon Werner Heringer Gutierrez
Ramon Werner Heringer Gutierrez
HGHelyel Rodrigues Gobbo
Helyel Rodrigues Gobbo
AJAlexandre Yamada Fujimura Júnior
Alexandre Yamada Fujimura Júnior
LHLuzimagno da Fonseca Lemos Heringer
Luzimagno da Fonseca Lemos Heringer

1 January 2025 in Arquivos Brasileiros de Oftalmologia
Verified
Journal Article
Open access
LCLaura Goldfarb Cyrino
Laura Goldfarb Cyrino
Dillan Cunha AmaralDillan Cunha Amaral
Dillan Cunha Amaral
AJAlexandre Yamada Fujimura Júnior
Alexandre Yamada Fujimura Júnior
BPBela J. Parekh
Bela J. Parekh
MBMarcela Marino de Azeredo Bastos
Marcela Marino de Azeredo Bastos
MHMarianna Almeida Hollaender
Marianna Almeida Hollaender
The advantages and disadvantages of using perioperative subconjunctival steroid injections in dropless cataract surgery continue to be debated. A systematic review of PubMed, EMBASE, and the Cochrane Central database identified five studies-two randomized controlled trials and three non-randomized studies-encompassing 70,751 eyes. Among these, 12,319 eyes (17.4%) received subconjunctival steroid injections, while 58,432 eyes (82.6%) were managed with topical steroids. The Cochrane Collaboration's RoB 2 tool was applied for bias assessments in randomized controlled trials, and heterogeneity was assessed using the I² statistics. No statistically significant differences were found between the two groups regarding macular edema (p=0.249), visual acuity (p=0.73), or laser flare count (p=0.45). Both subconjunctival injections and topical steroids demonstrated comparable efficacy and safety in controlling postoperative inflammation after cataract surgery. Additional research is warranted to validate these conclusions.

16 January 2025 in Ophthalmic Plastic & Reconstructive Surgery
Verified
Journal Article
Closed access
AFAlexandre Yamada Jr B.M.Sc. Fujimura
Alexandre Yamada Jr B.M.Sc. Fujimura
LCLaura Goldfarb Cyrino
Laura Goldfarb Cyrino
VRVitor Expedito B.M.Sc. Alves Ribeiro
Vitor Expedito B.M.Sc. Alves Ribeiro
DADillan Cunha B.M.Sc. Amaral
Dillan Cunha B.M.Sc. Amaral
RMRenata Martins Maia
Renata Martins Maia
SMSuzana M.D. Matayoshi
Suzana M.D. Matayoshi
Purpose: This study investigates the role of tranexamic acid in oculoplastic surgery. Methods: The authors searched PubMed, Embase, and Cochrane for randomized clinical trials comparing tranexamic acid (TXA) with placebo. They used the R software, applying mean difference for continuous outcomes and standard mean difference for continuous outcomes assessed on different scales. Results: The authors included 9 randomized clinical trials totaling 897 patients. Tranexamic acid did not reduce intraoperative bleeding, with a mean difference of −14.83 mL (95% confidence interval [CI]: −36.65 to 6.98). In the subgroup of patients undergoing dacryocystorhinostomy, there was a more pronounced trend, with a mean difference of −29.65 mL (95% CI: −61.07 to 1.76), though without statistical significance. In addition, TXA reduced the degree of periorbital ecchymosis, with a mean difference of −0.69 (95% CI: −1.13 to −0.25), and this reduction was more notable and only statistically significant with intravenous administration (mean difference of −0.78, 95% CI: −1.34 to −0.22). Regarding the surgeon’s satisfaction with hemostasis and the visibility of the surgical field, only 2 studies demonstrated statistically significant results, both using intravenous TXA administration. The other 4 studies did not report any improvement: 2 used the subcutaneous route, and the remaining 2 used the intravenous route for TXA administration. Finally, no reduction in the surgical time was observed with the use of TXA in oculoplastic procedures. Conclusions: In conclusion, TXA did not reduce intraoperative bleeding. However, despite the weak evidence in this outcome, the drug significantly decreased the degree of periorbital ecchymosis in patients undergoing blepharoplasty using intravenous administration.

1 April 2026 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
DVDavi Marçola Veiga
Davi Marçola Veiga
YIYuri Aleksander Ivanov
Yuri Aleksander Ivanov
AJAlexandre Yamada Fujimura Júnior
Alexandre Yamada Fujimura Júnior
MRMaria Eduarda Figueiredo Rebolho
Maria Eduarda Figueiredo Rebolho
BGBeatriz Gonçalves da Silva Miroski Gerente
Beatriz Gonçalves da Silva Miroski Gerente
Ricardo Noguera LouzadaRicardo Noguera Louzada
Ricardo Noguera Louzada
Purpose: This systematic review and meta-analysis aimed to comprehensively assess the acute effects of caffeine and caffeinated beverages on ocular microvasculature measured by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) parameters, explicitly focusing on subfoveal choroidal thickness (SFCT) and superficial capillary vessel density (SVD), and deep capillary vessel density (DVD). Methods: A systematic search was conducted across PubMed, the Cochrane Database, and Embase for trials evaluating the acute effects of caffeine or caffeinated beverages on SFCT, SVD, and DVD, as measured by OCTA. Pooled mean differences (MD) were calculated using random-effects models, with heterogeneity assessed by I2 statistics. Subgroup analyses were performed by study design, intervention type, and refractive status. The protocol was prospectively registered in PROSPERO (CRD420251091123). Statistical analyses were performed using RStudio 2025.05.1+513. Results: 18 studies comprising 630 patients were included. Pooled analysis demonstrated a significant reduction in SFCT after caffeine intake (– 23.79 μm; 95% CI: – 31.43 to – 16.15; p < 0.001), particularly with coffee and caffeine capsules, whereas no effect was observed with energy drinks or in highly myopic eyes. Regarding SVD, caffeine was associated with significant reductions across foveal, parafoveal, and perifoveal regions, mainly driven by coffee and capsule interventions. In DVD analyses, no overall significant effect was found; however, subgroup analyses indicated significant reductions with caffeine capsules and coffee, while energy drinks showed opposite trends. Conclusion: Acute caffeine intake, primarily from capsules or coffee, induces significant SFCT reduction and modest reductions in SVD, while changes in DVD were confined mainly to the caffeine-capsule subgroup, suggesting that energy drink ingredients may counteract caffeine-induced vasoconstriction. These findings offer valuable insights into the acute effects of caffeine on ocular microvasculature; however, the modest effect sizes necessitate caution regarding inherent physiological, measurement, and bioactive components variability. This study establishes a foundation for future investigations into the clinical significance of acute ocular microvascular fluctuations following caffeine intake.